Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Neurocrine Biosciences Inc issues FY 2014 earnings guidance below analysts' estimates


Thursday, 6 Feb 2014 11:01am EST 

Neurocrine Biosciences Inc:Expects FY 2014 net loss to be $56 mln to $61 mln, or $0.82 to $0.90 loss per share based on 68 million basic shares outstanding.FY 2014 net income of $(27.3) mln and EPS of $(0.37) - Thomson Reuters I/B/E/S. 

Company Quote

16.07
0.23 +1.45%
29 Sep 2014